Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

Neuropathic pain is a significant problem with few effective treatments lacking adverse effects. The sigma-1 receptor (S1R) is a potential therapeutic target for neuropathic pain, as antagonists for this receptor effectively ameliorate pain in both preclinical and clinical studies. The current resea...

Full description

Bibliographic Details
Main Authors: Lisa L. Wilson, Shainnel O. Eans, Insitar Ramadan-Siraj, Maria N. Modica, Giuseppe Romeo, Sebastiano Intagliata, Jay P. McLaughlin
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:International Journal of Molecular Sciences
Subjects:
sigma
sigma-1 receptor
antagonist
allodynia
analgesia
neuropathic pain
Online Access:https://www.mdpi.com/1422-0067/23/2/615

Internet

https://www.mdpi.com/1422-0067/23/2/615

Similar Items